Biofrontera Inc.
BFRI
$0.7874
-$0.0136-1.70%
| Weiss Ratings | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.22 | |||
| Price History | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.03% | |||
| 30-Day Total Return | -29.06% | |||
| 60-Day Total Return | -29.06% | |||
| 90-Day Total Return | 3.74% | |||
| Year to Date Total Return | -27.76% | |||
| 1-Year Total Return | -53.68% | |||
| 2-Year Total Return | -93.92% | |||
| 3-Year Total Return | -98.92% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -67.60% | |||
| 52-Week Low % Change | 20.90% | |||
| Price | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.43 | |||
| 52-Week Low Price | $0.65 | |||
| 52-Week Low Price (Date) | Nov 18, 2024 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.99M | |||
| Enterprise Value | 6.00M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.28 | |||
| Earnings Per Share Growth | -72.94% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.16 | |||
| Price/Book (Q) | 1.58 | |||
| Enterprise Value/Revenue (TTM) | 0.16 | |||
| Price | $0.79 | |||
| Enterprise Value/EBITDA (TTM) | -0.36 | |||
| Enterprise Value/EBIT | -0.35 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 7.57M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 245 1325 | |||
| Address | 120 Presidential Way Woburn, MA 01801 | |||
| Website | www.biofrontera-us.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -46.11% | |||
| Profit Margin | -47.58% | |||
| Management Effectiveness | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -43.00% | |||
| Return on Equity | -- | |||
| Income Statement | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 37.32M | |||
| Total Revenue (TTM) | 37.32M | |||
| Revenue Per Share | $4.93 | |||
| Gross Profit (TTM) | 18.72M | |||
| EBITDA (TTM) | -16.79M | |||
| EBIT (TTM) | -17.21M | |||
| Net Income (TTM) | -17.76M | |||
| Net Income Avl. to Common (TTM) | -17.76M | |||
| Total Revenue Growth (Q YOY) | 18.53% | |||
| Earnings Growth (Q YOY) | -139.59% | |||
| EPS Diluted (TTM) | -4.28 | |||
| EPS Diluted Growth (Q YOY) | -122.43% | |||
| Balance Sheet | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.91M | |||
| Cash Per Share (Q) | $0.78 | |||
| Total Current Assets (Q) | 20.70M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.43M | |||
| Current Ratio (Q) | 1.722 | |||
| Book Value Per Share (Q) | $0.50 | |||
| Total Assets (Q) | 22.10M | |||
| Total Current Liabilities (Q) | 12.02M | |||
| Total Debt (Q) | 4.92M | |||
| Total Liabilities (Q) | 17.67M | |||
| Total Common Equity (Q) | 4.43M | |||
| Cash Flow | BFRI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -3.00K | |||
| Cash from Financing (TTM) | 14.84M | |||
| Net Change in Cash (TTM) | 4.56M | |||
| Levered Free Cash Flow (TTM) | -6.35M | |||
| Cash from Operations (TTM) | -10.27M | |||
